---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024450"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:14:11.319721+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 kills aggressive human leukemia cells in vitro; expands oncology profile into blood cancers

## Summary
- Telomir-1 produced dose-dependent reduction in viability of human HL60 leukemia cells (aggressive AML model).
- Leukemia cells depend on intracellular iron; Telomir-1 lowers intracellular Fe²⁺ more potently than DFO.
- Prior research shows Telomir-1 reduces abnormal DNA methylation of tumor-suppressor genes and inhibits KDM histone demethylases.
- Findings add to previously reported activity against triple-negative breast, pancreatic, and prostate cancer models.

## SEC filing metadata
- accession: 0001493152-25-024450
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225024450/0001493152-25-024450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225024450/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024450
- JSON: https://secwatch.observer/filing/0001493152-25-024450.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.